Chargement en cours...
First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile
Tyrosine kinase inhibitors are de facto the more used targeted therapies for upfront treatment of metastatic renal cell carcinoma (mRCC). Among these, sunitinib and pazopanib have reported greater activity in term of progression-free survival and overall survival compared with interferon-α or placeb...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Landes Bioscience
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3938518/ https://ncbi.nlm.nih.gov/pubmed/24253418 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.27150 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|